HSD17B13 RNAi Treatment for Non-Alcoholic Fatty Liver Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) are inadequate in effectively reducing hepatic lipid droplet protein 17p-hydroxysteroid dehydrogenase type 13 (HSD17B13) expression, which contributes to hepatic inflammation and liver damage.
Innovation Solution
Administration of a double-stranded oligonucleotide linked to a ligand, such as N-acetyl-galactosamine, that targets hepatocytes to reduce HSD17B13 expression through RNA interference, thereby decreasing HSD17B13 mRNA and protein levels, using compounds like HSD17B13 RNAi agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for NAFLD, then treatment is provided, but HSD17B13 expression is not effectively reduced
Solution Approach 1:
The patent extracts and targets the specific HSD17B13 gene expression pathway using siRNA molecules that selectively silence this gene, separating the therapeutic action from non-specific treatments. This targeted extraction of the problematic gene expression leads to effective reduction of HSD17B13 protein levels and associated hepatic damage markers.
Solution Approach 2:
The patent uses an intermediary delivery system comprising lipids and carriers that facilitate the transport of siRNA molecules into hepatocytes. This intermediary mechanism ensures efficient delivery of the therapeutic agent to the target cells, enabling effective HSD17B13 expression reduction that would not be achieved through direct administration alone.
2Object-affected harmful factors
If HSD17B13 expression is reduced, then hepatic inflammation and liver damage are alleviated, but treatment complexity increases
Solution Approach 1:
The patent employs short-lived siRNA molecules that are designed to be degraded after performing their therapeutic function of silencing HSD17B13 expression. This disposable approach allows for effective treatment without requiring complex long-term delivery systems or persistent therapeutic agents, simplifying the overall treatment architecture while maintaining efficacy.
Solution Approach 2:
The patent utilizes parameter changes in the chemical structure and delivery characteristics of the therapeutic agent to optimize effectiveness. By adjusting parameters such as lipid composition, siRNA sequence, and delivery timing, the treatment achieves effective HSD17B13 reduction with manageable complexity, balancing therapeutic benefit with treatment feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment leads to a significant reduction in HSD17B13 expression, alleviating hepatic inflammation and liver damage, as evidenced by decreased ALT and AST levels, with a near maximal reduction of up to 90% at doses of 100-200 mg, and is safe with minimal off-target effects.
Implementation Method 1
Administration of a double-stranded oligonucleotide linked to a ligand, such as N-acetyl-galactosamine, that targets hepatocytes to reduce HSD17B13 expression through RNA interference
Data Source
AI summary
Described are methods of treatment of a non-alcoholic fatty liver disease via a reduction in HSD17B13 expression in a human subject in need of treatment.